StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(-92.25%)
USD 0.0
(-92.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 700.65 Thousand USD | -93.42% |
| 2021 | 10.64 Million USD | 25.13% |
| 2020 | 8.5 Million USD | 333.01% |
| 2019 | 1.96 Million USD | -20.96% |
| 2018 | 2.48 Million USD | -7.71% |
| 2017 | 2.69 Million USD | -21.74% |
| 2016 | 3.44 Million USD | 501.57% |
| 2015 | 572.14 Thousand USD | -80.48% |
| 2014 | 2.93 Million USD | -2.09% |
| 2013 | 2.99 Million USD | -70.19% |
| 2012 | 10.03 Million USD | 146.56% |
| 2011 | 4.07 Million USD | -18.49% |
| 2010 | 4.99 Million USD | -21.45% |
| 2009 | 6.35 Million USD | 6.2% |
| 2008 | 5.98 Million USD | -68.54% |
| 2007 | 19.03 Million USD | -10.18% |
| 2006 | 21.19 Million USD | 141.43% |
| 2005 | 8.77 Million USD | -33.24% |
| 2004 | 13.14 Million USD | 109.42% |
| 2003 | 6.27 Million USD | 204.11% |
| 2002 | 2.06 Million USD | -13.97% |
| 2001 | 2.39 Million USD | -40.98% |
| 2000 | 4.06 Million USD | 10534.31% |
| 1999 | 38.22 Thousand USD | -77.27% |
| 1998 | 168.21 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 583.73 Thousand USD | 53.99% |
| 2024 Q1 | 379.07 Thousand USD | 0.0% |
| 2023 Q1 | 683.86 Thousand USD | -2.4% |
| 2023 Q2 | 784.49 Thousand USD | 14.71% |
| 2023 Q3 | 508.42 Thousand USD | -35.19% |
| 2022 Q2 | 8.66 Million USD | -7.16% |
| 2022 Q1 | 9.33 Million USD | -12.34% |
| 2022 FY | 700.65 Thousand USD | -93.42% |
| 2022 Q4 | 700.65 Thousand USD | -91.66% |
| 2022 Q3 | 8.4 Million USD | -2.98% |
| 2021 FY | 10.64 Million USD | 25.13% |
| 2021 Q4 | 10.64 Million USD | 2.42% |
| 2021 Q3 | 10.39 Million USD | 62.08% |
| 2021 Q2 | 6.41 Million USD | -22.12% |
| 2021 Q1 | 8.23 Million USD | -3.22% |
| 2020 Q4 | 8.5 Million USD | 109.67% |
| 2020 FY | 8.5 Million USD | 333.01% |
| 2020 Q1 | 2.03 Million USD | 3.59% |
| 2020 Q2 | 4.9 Million USD | 141.05% |
| 2020 Q3 | 4.05 Million USD | -17.29% |
| 2019 Q4 | 1.96 Million USD | -45.3% |
| 2019 Q2 | 4.05 Million USD | 13.74% |
| 2019 Q1 | 3.56 Million USD | 43.57% |
| 2019 Q3 | 3.59 Million USD | -11.52% |
| 2019 FY | 1.96 Million USD | -20.96% |
| 2018 Q4 | 2.48 Million USD | 2.82% |
| 2018 FY | 2.48 Million USD | -7.71% |
| 2018 Q1 | 2.55 Million USD | -5.22% |
| 2018 Q2 | 3.23 Million USD | 26.64% |
| 2018 Q3 | 2.41 Million USD | -25.22% |
| 2017 Q4 | 2.69 Million USD | -7.51% |
| 2017 Q3 | 2.91 Million USD | -3.24% |
| 2017 FY | 2.69 Million USD | -21.74% |
| 2017 Q1 | 3.21 Million USD | -6.68% |
| 2017 Q2 | 3 Million USD | -6.3% |
| 2016 Q1 | 2.96 Million USD | 418.14% |
| 2016 FY | 3.44 Million USD | 501.57% |
| 2016 Q4 | 3.44 Million USD | 49.66% |
| 2016 Q3 | 2.29 Million USD | -6.38% |
| 2016 Q2 | 2.45 Million USD | -17.13% |
| 2015 FY | 572.14 Thousand USD | -80.48% |
| 2015 Q4 | 572.14 Thousand USD | -63.8% |
| 2015 Q1 | 3.01 Million USD | 2.92% |
| 2015 Q2 | 2.72 Million USD | -9.68% |
| 2015 Q3 | 1.58 Million USD | -41.97% |
| 2014 Q2 | 1.16 Million USD | -20.03% |
| 2014 FY | 2.93 Million USD | -2.09% |
| 2014 Q1 | 1.45 Million USD | -51.3% |
| 2014 Q4 | 2.93 Million USD | -37.65% |
| 2014 Q3 | 4.69 Million USD | 303.24% |
| 2013 FY | 2.99 Million USD | -70.19% |
| 2013 Q3 | 5.2 Million USD | -25.68% |
| 2013 Q1 | 8.58 Million USD | -14.48% |
| 2013 Q2 | 6.99 Million USD | -18.5% |
| 2013 Q4 | 2.99 Million USD | -42.45% |
| 2012 Q2 | 4.33 Million USD | 40.98% |
| 2012 Q3 | 3.57 Million USD | -17.57% |
| 2012 Q1 | 3.07 Million USD | -24.5% |
| 2012 Q4 | 10.03 Million USD | 181.03% |
| 2012 FY | 10.03 Million USD | 146.56% |
| 2011 FY | 4.07 Million USD | -18.49% |
| 2011 Q4 | 4.07 Million USD | -16.88% |
| 2011 Q1 | 4.07 Million USD | -18.45% |
| 2011 Q2 | 6.13 Million USD | 50.48% |
| 2011 Q3 | 4.89 Million USD | -20.09% |
| 2010 Q4 | 4.99 Million USD | 37.5% |
| 2010 FY | 4.99 Million USD | -21.45% |
| 2010 Q1 | 5.32 Million USD | -16.25% |
| 2010 Q2 | 4.01 Million USD | -24.56% |
| 2010 Q3 | 3.63 Million USD | -9.58% |
| 2009 Q2 | 3.6 Million USD | -34.5% |
| 2009 Q3 | 4.85 Million USD | 34.59% |
| 2009 FY | 6.35 Million USD | 6.2% |
| 2009 Q1 | 5.5 Million USD | -8.1% |
| 2009 Q4 | 6.35 Million USD | 31.09% |
| 2008 Q4 | 5.98 Million USD | -24.93% |
| 2008 FY | 5.98 Million USD | -68.54% |
| 2008 Q1 | 15.31 Million USD | -19.55% |
| 2008 Q2 | 11.91 Million USD | -22.2% |
| 2008 Q3 | 7.97 Million USD | -33.04% |
| 2007 Q3 | 21.76 Million USD | 7.22% |
| 2007 Q4 | 19.03 Million USD | -12.55% |
| 2007 FY | 19.03 Million USD | -10.18% |
| 2007 Q1 | 20.07 Million USD | -5.25% |
| 2007 Q2 | 20.29 Million USD | 1.1% |
| 2006 FY | 21.19 Million USD | 141.43% |
| 2006 Q1 | 6.88 Million USD | -21.53% |
| 2006 Q2 | 26.22 Million USD | 280.8% |
| 2006 Q3 | 24.01 Million USD | -8.42% |
| 2006 Q4 | 21.19 Million USD | -11.77% |
| 2005 Q2 | 10.1 Million USD | -8.46% |
| 2005 Q3 | 9.15 Million USD | -9.37% |
| 2005 Q4 | 8.77 Million USD | -4.12% |
| 2005 FY | 8.77 Million USD | -33.24% |
| 2005 Q1 | 11.03 Million USD | -16.07% |
| 2004 Q1 | 5.25 Million USD | -16.33% |
| 2004 Q3 | 8.74 Million USD | 121.07% |
| 2004 Q4 | 13.14 Million USD | 50.39% |
| 2004 FY | 13.14 Million USD | 109.42% |
| 2004 Q2 | 3.95 Million USD | -24.71% |
| 2003 FY | 6.27 Million USD | 204.11% |
| 2003 Q4 | 6.27 Million USD | 48.86% |
| 2003 Q3 | 4.21 Million USD | -11.68% |
| 2003 Q2 | 4.77 Million USD | 67.11% |
| 2003 Q1 | 2.85 Million USD | 28.82% |
| 2002 Q1 | 2.1 Million USD | 8.98% |
| 2002 Q3 | 2.05 Million USD | -16.33% |
| 2002 Q4 | 2.21 Million USD | 8.18% |
| 2002 FY | 2.06 Million USD | -13.97% |
| 2002 Q2 | 2.45 Million USD | 16.44% |
| 2001 Q3 | 2.17 Million USD | -9.2% |
| 2001 Q4 | 1.93 Million USD | -11.36% |
| 2001 Q1 | 2.74 Million USD | -13.39% |
| 2001 FY | 2.39 Million USD | -40.98% |
| 2001 Q2 | 2.39 Million USD | -12.46% |
| 2000 Q3 | 3.31 Million USD | 0.0% |
| 2000 FY | 4.06 Million USD | 10534.31% |
| 2000 Q1 | 55.83 Thousand USD | 46.05% |
| 2000 Q4 | 3.16 Million USD | -4.56% |
| 1999 Q1 | 163.77 Thousand USD | 0.0% |
| 1999 FY | 38.22 Thousand USD | -77.27% |
| 1999 Q2 | 161.68 Thousand USD | -1.28% |
| 1999 Q3 | 162.34 Thousand USD | 0.41% |
| 1999 Q4 | 38.22 Thousand USD | -76.45% |
| 1998 FY | 168.21 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| American Bio Medica Corporation | 1.26 Million USD | 44.787% |
| Arrayit Corporation | 1 Million USD | 29.962% |
| Atlantic International Corp. | 4.43 Million USD | 84.207% |
| Biocept, Inc. | 30.87 Million USD | 97.731% |
| Bioqual, Inc. | 56.58 Million USD | 98.762% |
| CardioGenics Holdings Inc | 231.93 Thousand USD | -202.094% |
| DermTech, Inc. | 121.93 Million USD | 99.425% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 4.18 Billion USD | 99.983% |
| HTG Molecular Diagnostics, Inc. | 17.77 Million USD | 96.059% |
| iMD Companies, Inc. | 190.13 Thousand USD | -268.499% |
| IDenta Corp. | 1.52 Million USD | 54.184% |
| Interpace Biosciences, Inc. | 13.02 Million USD | 94.619% |
| Integrative Health Technologies, Inc. | 8.25 Million USD | 91.509% |
| InVitro International | 1.53 Million USD | 54.325% |
| Lumos Diagnostics Holdings Limited | 26.83 Million USD | 97.389% |
| Many Bright Ideas Technologies Inc. | 2312.00 USD | -30205.017% |
| Medical Imaging Corp. | 4.19 Million USD | 83.284% |
| NovelStem International Corp. | 2.25 Million USD | 68.923% |
| Optigenex Inc. | 1.88 Million USD | 62.895% |
| PharmChem, Inc. | 2.76 Million USD | 74.665% |
| Proteome Sciences plc | 14.58 Million USD | 95.196% |
| Response Genetics, Inc | 48.88 Million USD | 98.567% |
| Rennova Health, Inc. | 20.57 Million USD | 96.594% |
| RushNet, Inc. | 6.04 Million USD | 88.414% |
| ScreenPro Security Inc. | 1.26 Million USD | 44.453% |
| Stella Diagnostics Inc. | 472.42 Thousand USD | -48.31% |
| Todos Medical Ltd. | 15.26 Million USD | 95.411% |